PLEASANTON, Calif., April 12, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.  The news release with the financial results will be accessible from the company's website prior to the conference call.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 4,500 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,750 issued patents and patent applications.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts 
Investors: This email address is being protected from spambots. You need JavaScript enabled to view it. 
Media: This email address is being protected from spambots. You need JavaScript enabled to view it.